Skip to main content

Advertisement

Table 1 Baseline characteristics of study population

From: Bleeding complications during cardiac electronic device implantation in patients receiving antithrombotic therapy: is there any value of local tranexamic acid?

Variables All patients (n = 135) Tranexamic acid (n = 52) Control (n = 83) P-value
Age (years) 60 ± 11 62 ± 10 59 ± 11 0.101
Male, n (%) 81 (60) 32 (61.5) 46 (59) 0.773
Body mass index (kg/m2) 25.4 ± 4.6 24.8 ± 4.0 25.8 ± 5.0 0.215
Smoking, n (%) 22 (16.3) 9 (17.3) 13 (15.7) 0.990
Hypertension, n (%) 74 (54.8) 29 (55.8) 45 (54.2) 0.860
Diabetes mellitus, n (%) 46 (34.1) 17 (32.7) 29 (34.9) 0.789
Previous CABG, n (%) 43 (31.9) 18 (34.6) 25 (30.1) 0.585
Ejection fraction, % 34 (20–55) 34 (20–55) 34 (20–55) 0.910
COPD, n (%) 19 (14.1) 9 (17.3) 10 (12.0) 0.548
Hemoglobin, g/dL 12.8 (9.5–15.1) 12.9 (9.5–14.5) 12.8 (9.5–15.1) 0.989
Platelet count, K/mm3 244 ± 57 240 ± 56 247 ± 58 0.476
BUN, mg/dL 30.6 (22–45) 30.6 (25–43) 30.6 (22–45) 0.926
Creatinine, mg/dL 1.1 ± 0.4 1.0 ± 0.4 1.1 ± 0.4 0.447
Atrial fibrillation, n (%) 43 (31.9) 22 (42.3) 21 (25.3) 0.039
Metallic prosthetic valve, n (%) 54 (40.0) 20 (38.5) 34 (41.0) 0.773
LV thrombus, n (%) 9 (6.7) 6 (11.5) 3 (3.6) 0.087
Recent stent implantation, n (%) 63 (46.7) 27 (51.9) 36 (43.4) 0.333
Medications
ACEI/ARB, n (%) 95 (70.4) 36 (69.2) 59 (71.1) 0.818
Beta blocker, n (%) 112 (83) 43 (82.7) 69 (83.1) 1.0
Diuretic, n (%) 99 (73.3) 37 (71.2) 62 (74.7) 0.800
Spironolactone, n (%) 67 (49.6) 25 (48.1) 42 (50.6) 0.775
Statin, n (%) 62 (45.9) 24 (46.2) 38 (45.8) 0.966
Warfarin, n (%) 72 (53.3) 25 (48.1) 47 (56.6) 0,333
DAPT, n (%) 37 (27.4) 16 (30.8) 21 (25.3) 0.621
Warfarin plus DAPT, n (%) 26 (19.3) 11 (21.2) 15 (18.3) 0.828
  1. ACEI angiotensin converting enzyme inhibitors, ARB angiotensin receptor blockers, BUN blood urea nitrogen, CABG coronary artery bypass graft, COPD chronic obstructive pulmonary disease, DAPT dual antiplatelet therapy, LV left ventricular